Joint analysis of multiple traits has recently become popular since it can increase statistical power to detect genetic variants and there is increasing evidence showing that pleiotropy is a widespread phenomenon in complex diseases. Currently, most of existing methods test the association between multiple traits and a single common variant. However, the variant-by-variant methods for common variant association studies may not be optimal for rare variant association studies due to the allelic heterogeneity as well as the extreme rarity of individual variants. In this article, we developed a statistical method by testing an optimally weighted combination of variants with multiple traits (TOWmuT) to test the association between multiple traits and a weighted combination of variants (rare and/or common) in a genomic region.
Abstract
Joint analysis of multiple traits has recently become popular since it can increase statistical power to detect genetic variants and there is increasing evidence showing that pleiotropy is a widespread phenomenon in complex diseases. Currently, most of existing methods test the association between multiple traits and a single common variant. However, the variant-by-variant methods for common variant association studies may not be optimal for rare variant association studies due to the allelic heterogeneity as well as the extreme rarity of individual variants. In this article, we developed a statistical method by testing an optimally weighted combination of variants with multiple traits (TOWmuT) to test the association between multiple traits and a weighted combination of variants (rare and/or common) in a genomic region.
TOWmuT is robust to the directions of effects of causal variants and is applicable to different types of traits. Using extensive simulation studies, we compared the performance of TOWmuT with the following five existing methods: gene association with multiple traits (GAMuT), multiple sequence kernel association test (MSKAT), adaptive weighting reverse regression (AWRR), single-TOW, and MANOVA. Our results showed that, in all of the simulation scenarios, TOWmuT has correct type I error rates and is consistently more powerful than the other five tests. We also illustrated the usefulness of TOWmuT by analyzing a whole-genome genotyping data from a lung function study. information from multiple variants. These methods include burden tests (Morgenthaler and Thilly 2007; Li and Leal 2008; Madsen and Browning 2009; Price et al. 2010; Zawistowski et al. 2010) , quadratic tests (Neale et al. 2011; Wu et al. 2011; Sha et al. 2012; Yang et al. 2017) , and combined tests (Derkach et al. 2013; Lee et al. 2013; Sha and Zhang 2014; Greco et al. 2015) .
As we pointed out above, it is essential to develop statistical methods to test the association between multiple traits and multiple variants (common and/or rare variants). Very recently, a few statistical methods for this purpose are appeared (Casale et al. 2015; Wang et al. 2015; Broadaway et al. 2016; Sun et al. 2016; Wang et al. 2016b; Wu and Pankow 2016) . Casale et al. [2015] proposed a set-based association test based on the linear mixed-model. This method enables jointly analyzing multiple correlated traits in rare variant association studies while accounting for population structure and relatedness. Wang et al. [2015] proposed a multivariate functional linear model approach to test association between multiple traits and rare variants in a genomic region. In this approach, the genetic effects of variants are treated as smooth functions of genomic positions of these variants.
Gene association with multiple traits (GAMuT) proposed by Broadaway et al. [2016] provide a nonparametric test of independence between a set of traits and a set of genetic variants. This method compares the similarities of multiple traits with the similarities of genotypes at variants in a genomic region. Multivariate Rare-Variant Association Test (MURAT) proposed by Sun et al. [2016] tests association between multiple correlated quantitative traits and a set of rare variants based on a linear mixed model. This method assumes that the effects of the variants follow a multivariate normal distribution with a zero mean and a specific covariance structure. Wu and Pankow [2016] extended the commonly used sequence kernel association test (SKAT) (Wu et al. 2011 ) for a single trait to multiple traits and proposed multiple sequence kernel association test (MSKAT). Wang et al. [2016b] proposed an adaptive weighting reverse regression (AWRR) method. This method uses the score test based on the reverse regression, in which the summation of adaptively weighted genotypes is treated as the response variable and multiple traits are treated as independent variables.
In this article, we developed a new statistical method by testing an optimally weighted combination of variants with multiple traits (TOWmuT) to test the association between multiple traits and a weighted combination of variants (rare and/or common) in a genomic region. TOWmuT is based on the score test under a linear model, in which the weighted combination of variants is treated as the response variable and multiple traits including covariates are treated as independent variables. The statistic of TOWmuT is the maximum of the score test statistic over weights. The weights at which the score test statistic reaches its maximum are called the optimal weights. TOWmuT is applicable to different types of traits and can include covariates. Using extensive simulation studies, we compared the performance of TOWmuT with single-TOW (Sha et al. 2012) , GAMuT (Broadaway et al. 2016) , MSKAT (Wu and Pankow 2016) , AWRR (Wang et al. 2016b ) and
MANOVA (Yang and Wang 2012) . Our results showed that, in all the simulation scenarios, TOWmuT is either the most powerful test or comparable to the most powerful test among the six tests. We also illustrated the usefulness of TOWmuT by analyzing a real whole-genome genotyping data from a lung function study.
Methods
We consider a sample with n unrelated individuals. Each individual has K potentially correlated quantitative or qualitative traits (1 for cases and 0 for controls for a qualitative trait) and has been genotyped at M variants in a genomic region. Let 
. For the th i individual, we consider a linear combination of the variants
are weights and their values will be decided later.
Without covariates
We first describe our method without covariates. Consider the linear model
The score test statistic to test the null hypothesis 0 1 : 0
. We define the test statistic of TOWmuT as
corresponding to the largest eigenvalue, then
is the optimal weights. Actually, we do not need to calculate 0 w in order to calculate
We use a permutation test to evaluate the p-value of TOWmuT T . In details, we randomly shuffle the traits in each permutation. Note that C and   
With covariates
Assume that there are p covariates and 1 , ,
denote the p covariates of the th i individual. Consider the linear model
In the appendix, we showed that under model (1), the score test statistic with covariates to test the null hypothesis 0 1 : 0
We can see the score test statistic with covariates
That is, replacing ik y and im x by their residuals ik y  and im x  in the score test statistic without covariates score T , it becomes the score test statistic with covariates c score T .
Therefore, we define TOWmuT statistic with covariates as
In summary, to apply TOWmuT with covariates, we adjust both trait value ik y and genotypic score im x for the covariates by applying linear regressions in (2) and apply TOWmuT without covariates to the residuals ik y  and im x  .
Comparison of Methods
We compare the performance of our method with the following methods: Multivariate MANOVA: Consider a multivariate multiple linear regression model:
where Y denotes the n K  matrix of phenotypes; X denotes the n M  matrix of genotypes;  is a M K  matrix of coefficients;  is the n K  matrix of random errors with each row of  to be i.i.d. 
is estimated using a permutation procedure.
Simulations
In our simulation studies, we use the empirical Mini-Exome genotype data provided by the genetic analysis workshop 17 (GAW17) 
A is a matrix with elements of 1, I is the identity matrix, and  is the correlation between i f and j f ; R is the number of factors; γ is a K by R matrix; c is a constant number;
is a vector of residuals; and 1 , ,
We consider the following six models with different number of factors and different number of traits affected by genotypes. In these models, the within-factor correlation is 2 c and the between-factor correlation is
Model 1: There is only one factor and genotypes impact on 6 traits with the same effect size. This is equivalent to set 1 R  and
. In details, 
Model 2: There are five factors and genotypes impact on 6 traits. We set 5 R  and 
Model 3: There are two factors and genotypes impact on 6 traits. That is, 
Model 5: There are only two factors and genotypes impact on one trait. That is, 
Results
To evaluate the type I error rates of the proposed test TOWmuT, we set 0 k   for , , 1 k K   in the 6 models. We consider different sample sizes, different significance levels, different models, and different types of traits. In our simulations we consider 10 traits (K = 10). In each simulation scenario, the p-values of TOWmuT are estimated by 1000 permutations and the type I error rates of TOWmuT are evaluated using 10,000 replicated samples. For 10,000 replicated samples, the 95% confidence intervals (CIs) for the estimated type I error rates of nominal levels 0.05 and 0.01 are (0.046, 0.054) and (0.008, 0.012), respectively. The estimated type I error rates of TOWmuT are summarized in Tables 1 and 2. From these two tables, we can see that 70 out of 72 (greater than 95%) estimated type I error rates are within the 95% CIs and the two estimated type I error rates not within the 95% CIs (0.05555 and 0.01295) are very close to the bound of the corresponding 95% CI, which indicates that TOWmuT is valid.
For power comparisons, we consider different values of heritability, different models, different types of traits, different percentages of protective variants, different values of between-factor correlation, and different values of within-factor correlation.
In each of the simulation scenarios, the p-values of TOWmuT, AWRR and single-TOW are estimated using 1,000 permutations and the p-values of MANOVA, GAMuT, and MSKAT are estimated using asymptotic distributions. The powers of all of the six tests are evaluated using 1,000 replicated samples at a significance level of 0.05. Figure 1 gives the power comparisons of the six tests (Single-TOW, MSKAT, AWRR, MANOVA, GAMuT, and TOWmuT) for the power as a function of the total heritability based on the six models for 10 quantitative traits. This figure shows that (1) TOWmuT is consistently the most powerful one among the six tests; (2) MANOVA is the second most powerful when genotypes impact on multiple traits (models 1-3 and 6) while AWRR is the second most powerful when genotypes impact on a single trait (models 4-5); (3) MSKAT is consistently less powerful than other multivariate tests probably because SKAT gives larger weights than that of TOW to only those variants with MAF in the range (0.01,0.035) and there are only 8% variants with MAF in the range (0.01,0.035) in Sgene which our simulations are based on; and (4) MSKAT and GAMuT have similar powers in all six models. Figure 2 gives the power comparisons of the five tests (Single-TOW, AWRR, MSKAT, GAMuT, and TOWmuT) for the power as a function of the total heritability for the mixture of 5 quantitative traits and 5 qualitative traits. We only compare the powers of five tests because MANOVA has inflated type I error rate in this case. This figure shows that (1) TOWmuT is consistently the most powerful one among the five tests; (2) AWRR is second most powerful when genotypes impact on multiple traits (models 1-3 and 6) while MSKAT and GAMuT are second most powerful when genotypes impact on a single trait (models 4-5); (3) MSKAT and GAMuT have similar powers in all six models; and (4) single-TOW is consistently less powerful than other four multivariate tests because we keep correlations between traits similar to that in Figure 1 such that correlations between original quantitative traits are larger than that in Figure 1 .
We also compare the powers of the six tests for the power as a function of the within-factor correlation for models 1-5 and between-factor correlation for model 6 for 10 quantitative traits ( Figure S1 ). As shown in this figure, the power of single-TOW is robust to the between-factor correlation or the within-factor correlation since the minimum p-value-based approach is largely unaffected by the trait correlation (Wu and Pankow 2016) . However, with the increasing of the between-factor correlation or within-factor correlation, the power of other five tests essentially increases. Other patterns of the power comparisons are similar to those of in Figure 1 .
Power comparisons of the six tests for the power as a function of the percentage of protective variants for 10 quantitative traits are given by Figure S2 .
This figure shows that the power of all six tests are robust to the percentage of protective variants, therefore, all of these methods are robust to the directions of the genetic effects. Other patterns of the power comparisons are similar to those of in Figure 1 .
Application to the COPDGene
Chronic obstructive pulmonary disease (COPD) is a common disease in elderly patients that causes significant morbidity and mortality (Nazir and Erbland 2009 ).
The Genetic Epidemiology of COPD Study (COPDGene) (Regan et al. 2010 ) was designed to identify genetic factors associated with COPD. In this COPDGene study, a total of more than 10,000 subjects have been enrolled including 2/3 non-Hispanic Whites (NHW) and 1/3 African-Americans (AA). In this analysis, we only include 5,430 NHW with no missing phenotypes. Each of the 5,430 NHW has been genotyped at 630,860 SNPs. Based on the literature studies of COPD (Han et al. 2011; Chu et al. 2014; Liang et al. 2016) , we selected 7 key quantitative COPDrelated phenotypes, including FEV1 (% predicted FEV1), Emphysema (Emph), Emphysema Distribution (EmphDist), Gas Trapping (GasTrap), Airway Wall Area (Pi10), Exacerbation frequency (ExacerFreq), Six-minute walk distance (6MWD), and 4 covariates, including BMI, Age, Pack-Years (PackYear) and Sex.
To evaluate the performance of our proposed method on a real data set, we applied six methods (TOWmuT, MANOVA, MSKAT, GAMuT, AWRR, and single-TOW) to the COPDGene of NHW population to test the association between each of 50-SNP blocks and the 7 key quantitative COPD-related phenotypes. To identify significant 50-SNP blocks associated with the phenotypes, we used Bonferroni correction to decide the significance level. The total number of 50-SNP blocks is 12617, therefore, the Bonferroni corrected significance level is 0.05/12617  4×10 -6 . Table 3 summarized the significant blocks identified by at least one method. There were total six significant blocks in Table 3 . All of the six blocks have been previously reported to be in association with COPD or lung functions (Pillai et al. 2009; Cho et al. 2010; Figarska et al. 2014; Lutz et al. 2015) . PDSS1 and ABI1 are located between LOC107984176 and LOC105376467, which are Intergenic regions and contain the SNPs associated with pulmonary function (Imboden et al. 2012; Lutz et al. 2015) . From Table 3 , we can see that TOWmuT identified four blocks; AWRR identified two blocks; MANOVA, MSKAT and GAMuT identified one block; single-TOW did not identify any blocks. From these results, we can see that TOWmuT identified the most of significant 50-SNP blocks among the six methods, which is consistent with the results of our simulation studies.
Discussion
We developed TOWmuT to perform joint analysis of multiple traits in gene-based association studies based on the following reasons: (1) multiple related traits are usually measured in genetic association studies of complex diseases; (2) there is increasing evidence showing that pleiotropy is a widespread phenomenon in complex diseases; and (3) there is a shortage of gene-based approaches for multiple traits. We used extensive simulation studies to compare the performance of TOWmuT with MANOVA, MSKAT, AWRR, GAMuT and Single-TOW. Our results showed that TOWmuT has correct type I error rates and is consistently more powerful than other five methods. Additionally, the real data analysis results demonstrated that the proposed method has great potential in gene-based association study for complex diseases with multiple phenotypes such as COPD.
Recently, it has become a major focus of investigation to identify a small number of rare causal variants that contribute to complex diseases (Capanu and Ionita-Laza 2015) . Several methods to pinpoint the causal variants have been developed for testing the association with a single trait. These methods include backward elimination (BE) method (Ionita-Laza et al. 2014) , hierarchical model method (Ionita-Laza et al. 2014) , and adaptive combination of p-values method (Lin 2016) . To extend the TOWmuT method to identify a small number of causal variants which are associated with multiple traits, we can use the BE method. In each step, we remove one variant that has the smallest contribution to the association between multiple traits and the set of variants and then we evaluate the p-value for testing association between multiple traits and the remaining variants by TOWmuT. Causal variants are the set of variants corresponding to the smallest p-value.
The computation time required for running TOWmuT depends on the sample size, the number of variants in the genomic region, the number of traits, and the number of permutations. The running time of TOWmuT with 1000 permutations on a data set with 5000 individuals, 7 traits and 10 variants in a genomic region on a laptop with 4 Intel Cores @ 3.30GHz and 4 GB memory is about 0.14s. To perform genome-wide association studies, we can first select genomic regions that show evidence of association based on a small number of permutations (e.g. 1,000), and then a large number of permutations are used to test the selected regions.
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